12:00 AM
 | 
Dec 04, 2000
 |  BC Week In Review  |  Company News  |  Other News

Maxim Pharmaceuticals other research news

MAXM received a $100,000 Phase I SBIR grant from the National Cancer Institute to conduct preclinical testing to treat...

Read the full 73 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >